Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
TETerns Pharmaceuticals, Inc. logo

Terns Pharmaceuticals, Inc. (TERN)

NASDAQ Global Select · Currency in USD
$52.95 ▼ -0.02 (-0.03%)
At close: May 15, 4:00 PM ET. Market closed.

Summary

Previous Close
$52.97
Open
$52.97
Day's Range
$52.95 – $52.97
52 Week Range
$2.66 – $53.19
Volume
6,331,482
Avg. Volume
5,918,999
Market Cap
$6.12B
Beta (5Y Monthly)
-0.38
PE Ratio (TTM)
--
EPS (TTM)
-$0.78
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$51.40

Profile: Terns Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
59
CEO
Amy L. Burroughs

Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH.

Earnings

DateEst.Actual
May 14, 2026-$0.30-$0.26Beat
Mar 30, 2026-$0.29-$0.25Beat
Nov 10, 2025-$0.30-$0.27Beat
Aug 5, 2025-$0.28-$0.26Beat
May 8, 2025-$0.29-$0.26Beat
Mar 20, 2025-$0.30-$0.24Beat

Analyst view

Consensus price target
$51.40 ▼ -2.9%
Range $14.00 – $70.00
Rating: Buy
Buy 63% · Hold 38% · Sell 0%

Get free alerts on TERN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.